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Purpose: The purpose of this paper was to investigate the effect of the oral administration of L-glycine (Gly) on the
development of diabetic cataract induced by streptozotocin (STZ) in rats.
Methods:  Two  groups  of  male  Wistar  rats  were  intraperitoneally  injected  with  a  single  dose  of  STZ  (65  mg/kg
bodyweight). Then, one group of diabetic rats and a control group were administered with 1% of Gly in drinking water
for three months, ad libitum. Cataract development was monitored biweekly through ophthalmoscope inspection and was
classified into four stages. At the end of 12 weeks, the animals were sacrificed and some biochemical parameters were
determined in their lenses. The parameters include advanced glycation end products (AGEs), glycated proteins, total and
soluble protein, glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), aldose reductase (AR), and sorbitol
dehydrogenase (SDH). Some parameters were also determined in the serum and blood of the rats.
Results: Diabetic cataract gradually progressed in the STZ-administered group with no other treatment. Consequently,
up to the end of the experiment, 2/3 of the animals in this group reached to the last stage of the cataract (mature cataract).
The progress of this process was much slower in the diabetic group that was treated with Gly. At the end of the study, the
visual cataract score was significantly lower in the diabetic group treated with Gly compared to those administered with
STZ. Some lens parameters, including glycated proteins, AGEs, SOD, and AR activities, were increased while some
others, including soluble and total protein, GSH level, and CAT activity, were decreased due to diabetes induction. After
Gly treatment, all the above-named parameters had reverse changes except for the CAT activity. The SDH activity in the
lenses had no changes due to diabetes or treatment. In addition, this treatment significantly decreased the amount of serum
glucose (Glc), serum AGEs, and glycated hemoglobin (HbA1c) in the diabetic rats. Gly also increased the ferric reducing
antioxidant power (FRAP) in the serum of diabetic rats. However, the decreased bodyweight of animals due to diabetes
induction was not compensated by Gly administration. It is important to note that Gly had no effect on normal rat
parameters.
Conclusions: The results indicated that the oral administration of Gly significantly delayed the onset and the progression
of diabetic cataract in rats. These effects were due to its antiglycating action and to a lesser extent, due to the inhibition
of oxidative stress and polyol pathway.
Chronic hyperglycemia is a major determinant in the
development of secondary complications of diabetes, such as
diabetic cataract. Evidence indicate that both the duration of
diabetes and the quality of glycemic control are the most
important risk factors for cataract formation [1]. Cloudiness
or opacification of the lens, which is responsible for focusing
light  and  for  producing  clear  and  sharp  images,  is  a
characteristic feature of a cataract. Cataract is the leading
cause of blindness across the world, especially in developing
countries. Because of the high prevalence of diabetes in these
countries, diabetic cataract may pose a major problem in the
management of blindness [2,3]. Today, the only treatments
for cataract are surgery and intraocular lens implantation,
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which are associated with significant cost and are not readily
available for everyone. In addition, these treatments may give
rise to serious complications, such as corneal edema, raised
intraocular pressure, and so on. The complications may occur
at  the  time  of  surgery  or  after  that  [4];  therefore,  the
identification of effective and non-toxic materials to prevent
opacification of the lens is still important for diabetes research
and pharmaceutical development.
The diffusion of extracellular glucose into the lens is not
controlled  by  insulin.  However,  different  mechanisms  are
involved in the development of cataract due to hyperglycemia
[5]. Among the proposed mechanisms for the opacification of
the lens, the posttranslational modification of the lens proteins
and  enzymes  through  reactions,  such  as  non-enzymatic
glycation, play a major role in cataractogenesis.
Non-enzymatic  glycation  involves  the  condensation
reaction of the carbonyl group of sugar aldehydes with the
NH2-terminus or free-amino groups of proteins. The initial
product  of  this  reaction  is  called  a  Schiff  base,  which
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439spontaneously  rearranges  itself  into  an  Amadori  product.
These compounds are relatively stable intermediates that can
undergo a series of complex reactions that may lead to the
formation of advanced glycation end products (AGEs) [6,7].
In some locations with limited protein turnover, such as in the
lens fiber cells, protein glycation due to hyperglycemia may
be  increased  up  to  tenfold  [8].  Glycation  causes  the
conformational  change,  aggregation,  and  cross-linking  of
proteins, which, in turn, leads to the formation of insoluble
materials  that  are  responsible  for  diabetic  cataract  [9].
Therefore, inhibition of this harmful process may prevent the
progression of diabetic complications, including cataract.
A wide variety of anti-cataractogenic agents, such as anti-
glycating  compounds  and  AGE  inhibitors,  have  been
investigated in several in vitro and in vivo studies [10]. The
role of amino acids in preventing diabetic complications was
suggested  [11].  The  preliminary  observations  about  the
reduced glycation of lens proteins by glucose or galactose in
the presence of certain amino acids are evidence [12,13]. In
addition, the anti-cataractous effect of lysine and the mixture
of some amino acids were shown in the animal model [14].
However,  a  comprehensive  study  about  the  anti-
cataractogenic  effect  of  glycine  (Gly)  is  not  seen  in  the
literature based on our review.
Our previous works focused on preventing the effect of
various  chemicals,  such  as  amino  acids,  on  diabetic
complications  [11,15-18].  In  the  present  study,  we
investigated the inhibitory effect of Gly on the progression of
eye lens opacification in STZ-diabetic rats for a period of 12
weeks.  At  the  end  of  the  experiment,  some  biochemical
parameters of the blood and lens of the animals were also
determined and the effect of Gly on diabetic cataract was
evaluated.
METHODS
Materials:  Streptozotocin  (STZ),  L-Glycine  (Gly),  Oxalic
acid,  5-hydroxymethylfurfural  (5-HMF),  2-thiobarbituric
acid  (TBA),  Triethanolamine,  nicotinamide  adenine
dinucleotide  phosphate  reduced  form  (NADPH),
nicotinamide adenine dinucleotide reduced form (NADH),
protein, and superoxide dismutase (SOD) quantification kits
were purchased from Sigma Chemical Company (St. Louis,
MO). All other chemicals and solvents were of analytical
grade.
Experimental design: The experiments were performed using
male Wistar rats (7–8 weeks old and weighing 213±21.5 g).
The rats were housed under a 12 h:12 h light-dark cycle at
about 25 °C, room temperature. All animals had unlimited
access to water. Animal care and protocols were in accordance
with  and  approved  by  the  Institutional  Animals  Ethics
Committee of Tarbiat Modares University and conformed to
the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research.
After one week, 20 rats were randomly selected as the
normal groups. Half of them were administered with Gly, as
diabetic group under treatment. These groups were named as
N and NG, respectively. Thirty-five of the rats were injected
intraperitoneally with a single dose of streptozotocin (STZ;
65 mg/kg of bodyweight) [14]. They were divided into two
groups with or without treatment with Gly and were named
DG and D, respectively. STZ was dissolved in 0.1 M of
sodium citrate buffer, with a pH of 4.5. It was kept on ice and
was used within 10 min of dissolving. The control groups of
rats (groups N and NG) were injected with the vehicle alone.
Three days after STZ administration, only the rats that have a
blood glucose level of >15 mmol/l were considered as diabetic
and were included in our experiments.
The treatment of the diabetic and normal groups (groups
DG and NG) with Gly (1% in drinking water) [19] was begun
after one week (time zero in the figures and tables). The
experiments lasted over 12 weeks.
Blood measurement: Blood samples were collected from the
orbit vein at the beginning, middle, and end of the study.
EDTA-treated whole blood samples were saved for HbA1c
determination  and  sera  samples,  prepared  through  15-min
centrifugation of blood at 5,000× g to separate clot, and stored
at −70 °C for further studies.
Sera  glucose  was  measured  using  the  enzymatic
colorimetric method (ELITech, SEES, France). For this, the
Autoanalyser Model Biotecnica BT 3500 (Biotecnica, Rome,
Italy) was employed. Glycated hemoglobin (HbA1c) in blood
samples were measured with the use of the reagent kit and
DS5 instrument of Drew Scientific Ltd. (Barrow-in-Furness,
Cumbria, UK).
Determination of AGEs was performed according to the
method of Kalousova et al. [20]. Blood serum was diluted 1:50
with PBS, pH 7.4. Flourescence intensity was recorded at the
emission maximum (440 nm) upon excitation at 350 nm using
the  spectrofluorometer  Shimadzu,  Model  RF  5000
(Shimadzu,  Kyoto,  Japan).  Fluorescence  intensity  was
expressed as a percentage of fluorescent emission (FI %).
The  reducing  ability  of  the  biologic  samples  was
determined  using  the  ferric  reducing  antioxidant  power
(FRAP) assay of Benzie and Strain [21]. The FRAP assay
measures the change in the absorbance of the FRAP reagent
at 593 nm (Spectrophotometer Shimadzu, Model 3101) due
to  the  formation  of  a  blue-colored  Fe  II-tripyridyltriazine
complex from colorless oxidized Fe III formed by the action
of electron-donating antioxidants in the serum.
Evaluation of cataract development: The progression of the
cataract  was  monitored  biweekly  using  a  handheld
ophthalmoscope that was equipped with a slit lamp by an
individual who had no prior knowledge of the affiliation of
the animal to the experimental group. Cataract formation was
scored essentially according to the classification of Ao et al.
[22] or Suryanarayana et al. [23] as follows: clear normal lens
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440(O), peripheral vesicles (I), peripheral vesicles and cortical
opacities  (II),  diffuse  central  opacities  (III),  and  mature
cataract (IV). Cataract formation was considered complete
(grade IV) when the red fundus reflex was no longer visible
through any part of the lens and when the lens appeared dull
white to the naked eye.
Lens preparation: At the end of 12 weeks, the animals were
killed  and  their  eyeballs  were  removed  for  biochemical
evaluation. The eyeballs were soaked in 0.9% neutral normal
saline  and  the  lenses  were  dissected  using  the  posterior
approach then placed into pre-weighed Eppendrof tubes and
frozen at −70 °C until further analysis. A 10% homogenate
was prepared from the lens in 50 mM phosphate buffer (pH
7.4). The activity of the lens enzymes and soluble protein were
measured  in  the  soluble  fraction  of  the  lens  homogenate
(15,000× g at 4 °C) while the lens AGEs and the total protein
were determined in the total homogenate.
Biochemical assays: The determination of the lens AGEs was
performed as described by Ranjan et al. [24]. Fluorescent
measurements were performed in the total lens homogenate
samples using a Spectrofluorometer Shimadzu, Model RF
5000  and  the  fluorescence  intensity  was  recorded  at  the
emission maximum (440 nm) upon excitation at 366 nm.
Results  were  expressed  as  a  percentage  of  fluorescent
emission (FI %).
Determination of the amount of glycated lens proteins
was based on the method described by Blakytny and Harding
[25].  The  5-hydroxymethylfurfural  (5-HMF)  was  released
into the solution due to the boiling of the glycated protein in
the presence of a weak acid. Any solubilized protein was then
precipitated out of the solution through centrifugation. After
the addition of thiobarbituric acid (TBA), it forms adduct with
5-HMF that absorbs at 443 nm. The amount of glycation was
determined using the standard graph that was drowned by
various concentrations of 5-HMF.
Measurement  of  free,  reduced  GSH  in  the  lens  was
performed  using  the  5,5′-dithiobis-[2-nitrobenzoic  acid]
(DTNB) method [26]. The lens was ground in 1 ml of 10%
trichloroacetic  acid  (TCA)  then  left  for  20  h  before
centrifugation at 11,500× g at room temperature for 20 min.
The supernatant was removed into a tube and the precipitate
was washed twice with 10% TCA. Then, the supernatants
were combined; 0.5 ml of supernatant from each sample was
made up to 1 ml by adding 10% TCA and 2 ml of 1 M Tris,
pH 9.0 followed by the addition of 50 μl DTNB (dissolved in
ethanol at a concentration of 3.965 mg/ml) and mixed well.
Standards were made using different volumes of 0.1 mM
reduced GSH in 10% TCA and making up to 1 ml with 10%
TCA. Reaction blanks consisted of 1.0 ml of 10% TCA, Tris,
and DTNB. The reaction solutions stood for 5 min at room
temperature and the absorbance was read at 412 nm. The
concentration of GSH was read from a standard graph using
GSH.
Lens  superoxide  dismutase  (SOD)  levels  were
determined using the method of Sun et al. [27], based on the
inhibition of nitroblue tetrazolium. In the assay, the xanthine-
xanthine oxidase system was used as a superoxide generator.
The absorbance of the reduction product (formazane dye) was
measured at 440 nm. The SOD activity was determined by the
degree  of  inhibition  of  this  reaction.  The  catalase  (CAT)
activity in the lens was assayed with hydrogen peroxide as the
substrate  using  a  method  that  was  based  on  the  direct
measurement of H2O2 decomposition [28].
Aldose  reductase  (AR)  and  sorbitol  dehydrogenase
(SDH) activities were estimated according to the methods
described by Kinoshita et al. [29] and Gerlach and Hiby [30],
respectively.
The total and soluble proteins of the lens were measured
using the method of Lowry and by using a protein assay kit
from Sigma Company.
Statistical analysis: Data was expressed as mean±SD. One-
way ANOVA was used for testing the statistical significance
between  groups.  Statistical  analysis  of  the  average  of  the
cataract score of the lens opacity was done using the Mann–
Whitney U-test. A p<0.05 was considered significant. All data
was dealt with using the SPSS 16.0 statistical package (IBM,
New York, NY).
RESULTS
General  parameters:  All  animals  in  the  normal  groups
(treated or untreated with exogenous Gly) lived up to the end
of  the  experiment.  Out  of  the  35  STZ-treated  rats,  32
contracted diabetes. Mortality in the experimental groups after
five and nine weeks was five (5 of 17) rats in the diabetic
groups and two (2 of 15) rats in the treated group administered
with Gly, respectively. Thus, 70.6% and 86.7% of the rats in
these groups and all of the animals in the control groups (with
or without treatment by Gly) remained up to the end of the
experiment.
Table 1 shows the changes in the bodyweights of all four
groups  of  animals  during  the  course  of  this  study.  The
bodyweights of the two diabetic groups were significantly
(p<0.01) lower than those of the normal groups and Gly had
no effect on this parameter (Figure 1).
Biochemical parameters in the serum or blood: Figure 2A
shows the changes in the serum glucose level of all four groups
of rats during the course of the experiment. The glucose level
in the sera of both diabetic groups are higher than the normal
group,  but  after  the  administration  of  Gly,  the  glucose
concentration reduced significantly (p<0.001) in the diabetic
group.
As seen in Figure 2B, the diabetic rats had a higher blood
HbA1c level than the normal rats throughout the experimental
period.  The  percentage  of  HbA1c  showed  no  significant
differences among diabetic rats until six weeks, but after 12
weeks, a significant (p<0.05) decrease in the mean percent of
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442HbA1c in diabetic rats treated with Gly in comparison with
the diabetic rats without treatment was observed.
The formation of the AGEs in the serum of the diabetic
groups increased gradually. However, it was decreased and
closed to the normal value in the diabetic group that was under
treatment with Gly. Significant differences were observed in
this parameter between the diabetic group and the other three
groups (p<0.01; Figure 2C).
The  results  of  the  FRAP  assay,  as  a  measure  of  the
antioxidant activity, in the serum of rats are shown in Figure
2D. It indicates that this parameter decreased significantly in
the diabetic group, but after 12 weeks of treatment with Gly,
it increased significantly (p<0.05).
Cataract  formation:  Figure  3A  shows  the  representative
photographs of the lenses from each group at the end of the
study. The onset of cataract in the diabetic group was observed
five weeks after STZ injection (Figure 3B). In the diabetic
Figure  1.  Changes  in  the  rat’s
bodyweight  during  the  course  of  the
experiment. The data shows the average
results in all the animals in a given group
at  a  given  time.  The  weights  of  the
normal  groups  were  significantly
different  from  those  of  the  diabetic
groups  (p<0.01)  and  there  were  no
significant differences between the two
diabetic groups at any time. N: normal
rats; D: diabetic rats; DG: diabetic rats
with Gly; and NG: normal rats with Gly.
Figure  2.  Changes  in  the  serum  and
blood  biochemical  parameters  in
different groups of rats at the different
times  of  the  experiment.  A:  Glucose
concentration, B: Percent of HbA1c, C:
Fluorescence  intensity  of  AGEs,  and
D: FRAP. N: normal rats; D: diabetic
rats;  DG:  diabetic  rats  with  Gly;  and
NG: normal rats with Gly. “a” indicates
the  significance  of  the  data  that
compares group N versus all groups. “b”
indicates the significance of the data that
compares  group  D  versus  groups  of
glycine-treated  rats.  *,  p<0.05;  #,
p<0.01; and †, p<0.001.
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443group, the rats developed cataract more or less at the same
rate. After eight weeks, 33.3% of the lenses of the untreated
diabetic rats were in grade II, 66.6% in grade III and none of
them were clear. Conversely, at this time, all the lenses in the
diabetic group that was treated with Gly were clear. On the
10th week, 33.3% of the lenses of the animals in group D
developed mature cataracts (grade IV) and 66.6% were in
grade III. The treatment of diabetic rats with Gly delayed the
onset of the cataract because 55.6% of the lenses of this group
were in grade I and 44.4% were clear at the end of the 10th
week. At the end of the experiment (week 12, Figure 3C), all
the  lenses  of  the  animals  in  the  untreated  diabetic  group
showed an advanced stage of cataract (grade III and IV). On
the other hand, in Gly-treated diabetic rats, 44.4% of the lenses
remained clear, 44.4% were in grade I and only 11.1% were
in grade II. All the lenses in the normal groups (group N and
NG) remained clear throughout the experimental period.
Biochemical parameters of the lens: There was an increase of
AGE  fluorescence  in  the  lenses  of  the  diabetic  group  in
comparison with the normal one. Gly significantly (p<0.001,
Table 2) decreased this parameter in diabetic rats.
Hyperglycemia causes an increase in the glycated protein
of the diabetic lenses. Significant differences in the glycated
protein between the normal group (group N) and the diabetic
group  (group  D)  were  noted.  Gly  administration  had  a
Figure 3. Effect of Gly therapy on the
opacity  of  the  lenses  in  STZ-diabetic
rats. A: Photographs of lenses from each
group  at  the  end  of  12  weeks.  B:
Progression of cataract in diabetic rats
throughout  the  experimental  period.
Cataract formation was scored biweekly
according  to  the  following
classification:  clear  normal  lens  (O),
peripheral  vesicles  (I),  peripheral
vesicles  and  cortical  opacities  (II),
diffuse central opacities (III) and mature
cataract (IV). The scores of cataracts in
each group were averaged at the given
time  and  the  average  score  of  the
cataract  was  plotted  as  a  function  of
time. There was a significant difference
(p<0.001) between the average score of
the cataract of groups D and DG from
six weeks to the end of the study. C:
Maturation of the cataract in diabetic
rats  after  12  weeks.  Cataract
development in rats was observed on
week 12 of the study and the number of
lenses that developed opacity against the
total number of lenses was considered
for  calculating  the  percentage  of
incidence of cataract in each group. N:
normal  rats;  D:  diabetic  rats;  DG:
diabetic rats with Gly; and NG: normal
rats with Gly.
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444significant (p<0.001; Table 2) effect on the decrease of the
formation of glycated protein in the diabetic rats that were
under treatment.
The total and soluble protein content in the lens of all four
groups was also determined. There was a significant decrease
of  both  total  and  soluble  protein  levels  in  diabetic  rats
compared to the normal rats (Table 2). Treatment with Gly
caused a significant (p<0.01) increase in the protein levels of
diabetic lenses.
The  amount  of  glutathione  (GSH),  which  acted  as  a
reducing peptide, and CAT, which acted as an antioxidant
enzyme, decreased in the lenses of untreated diabetic rats 13
weeks after STZ injection when they were compared with the
normal group (Table 3). Gly had a statistically significant
(p<0.05) effect in raising the amount of GSH in the diabetic
group that was under treatment. No significant changes were
observed in the CAT activity (Table 3). On the other hand, the
activity of the SOD increased in the lenses of the diabetic
group (Table 3) and significantly (p<0.05) decreased after the
treatment of this group with Gly.
AR is the key enzyme of the polyol pathway and its
activity was significantly higher in the diabetic group than in
the normal one. Meanwhile, the activity of the other enzyme
of this pathway, SDH, was not significantly altered (Table 4).
The treatment with Gly caused a significant (p<0.05) decrease
in the AR activity of diabetic rats, but had no effect on the
SDH activity.
DISCUSSION
Cataract is an opacity within the lens that interferes with
vision. It is the most frequent cause of visual impairment
throughout the world. This condition usually happens as a
consequence  of  diabetes  and  hyperglycemia  [5].
Hyperglycemia may be controlled in different ways, such as
TABLE 2. THE EFFECT OF GLYCINE ON THE AGE FLUORESCENCE EMISSION, GLYCATED PROTEIN, AND PROTEIN CONTENT OF RAT LENSES.
Group name Lens AGE (FI %) Glycated proteins (μmol
of HMF/mg pr)
Total protein (mg/lens) Soluble protein (mg/lens)
N 18.5±3.1 0.52±0.06 17.68±0.72 14.50±0.66
D 82.6±5.9a† 1.87±0.30a† 10.19±3.10a# 4.79±2.28a#
DG 23.7±4.9b† 0.86±0.15b† 16.69±2.02b# 8.25±0.84a,b#
NG 19.3±3.7b† 0.50±0.14b† 17.17±1.47b# 13.97±1.04b#
Data are expressed as the mean±SD (n=6). “a” indicates the significance of the data that compares group N versus all groups.
“b” indicates the significance of the data that compares group D versus groups of Glycine-treated rats. #, p<0.01; and †, p<0.001.
TABLE 3. THE EFFECT OF GLYCINE ON THE CONTENT OF GLUTATHIONE AND THE ACTIVITIES OF ANTIOXIDANT ENZYMES IN RAT
LENSES.
Group name GSH (mg/g lens) CAT activity (μmol/g lens
pr)
SOD activity (units/min/
mg lens pr)
N 178.0±36.9 59.8±8.6 6.20±0.20
D 51.0±14.8a† 31.7±11.5a# 15.39±5.34a†
DG 126.9±25.5b* 39.1±10.7 11.09±1.72a,b*
NG 175.0±23.6b† 55.7±13.2b* 6.50±0.45b†
        Data are expressed as the mean±SD (n=6). “a” indicates the significance of the data that compares group N versu all groups.
        “b” indicates the significance of the data that compares group D versus groups of Glycine-treated rats. *, p<0.05; #, p<0.01;
        and †, p<0.001.
TABLE 4. THE EFFECT OF GLYCINE ON THE ACTIVITIES OF THE POLYOL PATHWAY ENZYMES IN RAT LENSES.
Group name AR activity (μmol NADPH oxidized/hr/
100 mg pr)
SDH activity (μmol NADH oxidized/hr/
100 mg pr)
N 30.8±3.1 4.63±0.54
D 40.2±3.0a† 5.12±0.84
DG 32.8±2.3b* 5.14±0.59
NG 29.9±4.9b† 4.58±0.90
        Data are expressed as the mean±SD (n=6). “a” indicates the significance of the data that compares group N versus all groups.
        “b” indicates the significance of the data that compares group D versus groups of Glycine-treated rats. *, p<0.05; and †, p<0.001.
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445dietary changes, the use of hypoglycemic agents, insulin, and
through  islet  transplantation.  Cataract,  as  a  long-term
complication of diabetes, has remained a serious problem. At
present, the only treatment for cataract is surgery. If there is a
possibility that the onset of cataract can be delayed by 10
years, the need for cataract surgery may be decreased by as
much as half [31]. Therefore, any strategy that prevents or
slows down the progression of cataract can have a significant
impact on human health.
There  are  possible  mechanisms  involved  in  the
pathophysiology of diabetic cataract. These include increased
formation  of  advanced  glycation  end  products  (AGEs),
oxidative stress, and increased polyol pathway or osmotic
stress  [5].  Although  there  is  cross  talk  between  these
pathways, results of various studies suggest that glycation and
oxidative  stress  are  two  of  the  major  determinants  in  the
pathogenesis of diabetic cataract [24,32].
It  was  previously  shown  that  amino  acids  may  be
effective in the prevention of diabetes and its complications
[33]. It has also been shown that Gly has antioxidant properties
and  that  it  inhibits  non-enzymatic  glycation  [19,34-36].
Therefore,  as  a  continuation  and  follow  up  to  our  recent
investigation on the therapeutic and preventative effects of
some  chemicals  [11,16-18]  and  natural  products  [37]  on
diabetic complication, we used Gly to treat the STZ-induced
diabetic rats and investigated its effect on the prevention of
cataract in our present study.
As the results indicate, there were no differences between
the determined parameters in the normal rats (N) and in the
normal rats treated with Gly (NG). Therefore, Gly has no toxic
effect on healthy rats and it even decreased the mortality of
diabetic animals. The safe dose for Gly administration has
been reported previously by others [19,36]. In addition, our
data indicate the significant reduction of the serum Glc level
of diabetic rats after six weeks of treatment with Gly. A similar
effect  was  observed  on  the  diabetic  rats  that  were  orally
administered with Gly [19]. However, the specific mechanism
of Gly- induced diminution of blood Glc is still not known,
but the reaction of Gly with sugars, such as Glc has been
observed. This means that the non-enzymatic glycation of Gly
decreases the free Glc concentration in the medium [34]. In
addition,  in  humans,  it  has  been  found  that  glycine
administration increases the response to insulin [38]. Oral
glycine  stimulates  the  secretion  of  a  gut  hormone  that
potentiates the effect of insulin on glucose removal from the
circulation [39]. However, the serum glucose level of diabetic
rats treated with Gly is still high and is more than the threshold
(180 mg/dl) that is necessary for the induction of cataract
[40]. Our results also indicate that cataract was formed in the
diabetic  group  after  the  fifth  week  of  STZ  injection  and
progressed up to the end of study. However, the significant
decrease  in  the  cataract  score  is  seen  due  to  the  Gly
administration. Therefore, the observed delay of the onset and
inhibition  of  the  progression  of  cataract  after  the
administration of Gly in diabetic rats is possibly due to other
factors in addition to its Glc lowering property. To investigate
this hypothesis, various biochemical pathways related to the
formation of diabetic cataract were investigated.
A significant decrease was observed in the HbA1c and
AGEs of the diabetic group that was under treatment with Gly.
Similar results have been reported after six-month treatment
of diabetic rats with Gly [19,35]. We have also demonstrated
a  significant  decrease  in  HbA1c  and  AGEs  after  L-Lys
administration to the diabetic rats [11]. Gly administration
also significantly increased the FRAP in the serum of the
diabetic rats. A similar increase due to the administration of
Lys, aspirin, and spermine in diabetic rats have also been
shown by us in our previous studies [11,16,17]. The decreased
levels of HbA1c and AGEs in diabetic rats treated with the
above-named compounds, including Gly, should be explained
by their inhibitory effect on protein glycation [11,16,17,34],
thereby reducing the oxidative stress that is usually associated
with increased FRAP.
During  the  progression  of  the  cataract,  the  total  and
soluble protein content of the diabetic lenses was reduced
significantly. The reduction may be due to the formation of
high molecular weight aggregates of proteins, which may
have resulted from the occurrence of oxidative stress and the
cross link formation between protein free-SH groups, AGE
formation, and protein leakage after the increased activity of
the polyol pathway and from osmotic stress, which increased
membrane  permeability  [9,31].  As  our  results  show,  the
treatment of rats with Gly reduced protein glycation and AGEs
formation. It also significantly prevented the total and soluble
protein  loss  in  diabetic  lenses.  The  preventative  effect  of
glycine on the lens proteins glycation in the glucose-treated
homogenates of normal lenses was also shown previously
[34]. The suggested mechanism for this action of Gly, as
explained above, is its ability to bind excess Glc and reduce
its free concentration [34].
The  decreased  GSH  and  the  altered  activities  of  the
antioxidant enzymes, including CAT, are due to the increase
of oxidative stress in diabetic conditions. Such alteration was
also reported previously in various types of cataract, including
diabetic cataract [32]. A significant increase in the activity of
SOD in the lenses of diabetic rats was also reported previously
[41]. Gly, with its antiglycating and antioxidant activities,
could significantly increase the amount of GSH and decrease
the activity of SOD enzyme in diabetic rat lenses. In several
studies,  the  beneficial  effects  of  antioxidants,  such  as
curcumin, turmeric, N-acetylcysteine, and glutathione ethyl
ester, have been shown on the prevention of diabetic cataract
[31,32].
The dicarbonyl intermediates of the Maillard reaction,
such as glyoxal and methylglyoxal, as the substrates of AR,
are  produced  during  the  glycation  process.  When  these
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446compounds increase due to hyperglycemia, the activity of the
polyol pathway is also increased [42]. AGEs are also inducers
of AR and their increase during aging and diabetes are another
reason  for  the  enhancement  of  the  activity  of  the  polyol
pathway [43]. As our results indicate, the activity of the AR
was significantly increased due to diabetes induction and the
treatment  of  diabetic  rats  with  Gly  caused  a  significant
decrease in the formation of AGEs and the activity of this
enzyme. However, SDH activity was not significantly altered
in the diabetic group. A similar observation has also been
reported previously by Saraswat et al. [31]. They reported that
Zingiber officinalis have antiglycating property and that it can
reduce  non-enzymatic  glycation  and  AGEs  formation  in
diabetic rat lenses.
Finally, the beneficial effects of Gly on diabetic cataract
may be summarized as follows:
1. High solubility in comparison with some other
anti-cataract agents [36].
2. Hypoglycemic, antiglycating, and antioxidant
properties.
3. Having specific transporter in the cortex and
nuclear of lenses [44,45].
4. Physiologically available and nontoxic for non-
neuronal tissues [44].
In  conclusion,  the  present  study  shows  that  the
administration of Gly to diabetic rats delays the onset and the
progression  of  cataract  by  decreasing  protein  glycation,
preserving  protein  content,  potentiating  the  antioxidant
system, and decreasing the activity of the polyol pathway in
the lenses. Decreasing the serum Glc, AGE formation and
HbA1c, in addition to the increase in the FRAP are also other
reasons for the beneficial effect of Gly on diabetic cataract.
Gly  did  not  show  any  toxic  effect  on  the  above-named
parameters in the normal rats.
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